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Positional cloning of lymphopenia (lyp) in the BB rat revealed a frameshift mutation in Gimap5, a member of at least seven related
GTPase Immune Associated Protein genes located on rat chromosome 4q24. Our aim was to clone and sequence the cDNA of the
BB diabetes prone (DP) and diabetes resistant (DR) alleles of all seven Gimap genes in the congenic DR.lyp rat line with 2 Mb of
BBDPDNA introgressedontothe DR genetic background. All(100%) DR.lyp/lyp ratsarelymphopenicanddevelop type1 diabetes
(T1D) by 84 days of age while DR.+/+ rats remain T1D and lyp resistant. Among the seven Gimap genes, the Gimap5 frameshift
mutation, a mutant allele that produces no protein, had the greatest impact on lymphopenia in the DR.lyp/lyp rat. Gimap4 and
Gimap1 each had one amino acid substitution of unlikely signiﬁcance for lymphopenia. Quantitative RT-PCR analysis showed a
reduction in expression of all seven Gimap genes in DR.lyp/lyp spleen and mesenteric lymph nodes when compared to DR.+/+. Only
four; Gimap1, Gimap4, Gimap5,a n dGimap9 were reduced in thymus. Our data substantiates the Gimap5 frameshift mutation as
the primary defect with only limited contributions to lymphopenia from the remaining Gimap genes.
Copyright © 2009 Elizabeth A. Rutledge et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Lymphopenia (lyp) is a prerequisite for spontaneous type 1
diabetes (T1D) in the BioBreeding (BB) diabetes prone (DP)
rat [1]. Positional cloning of the lyp gene revealed a frame
shift mutation in Gimap5 (previously known as Ian5 or
Ian4L1).Gimap5isamemberofatleastsevenrelatedGTPase
Immune Associated Protein (Gimap) genes located within
150 Kilobases (Kb) on rat chromosome (RNO) 4 [2, 3].
DR.lyp/lyp rats, where 2Mb of DP DNA was introgressed
onto the BB diabetes resistant (DR) genetic background, are
lymphopenic and 100% develop spontaneous T1D by 84
days of age [4].
The positional cloning and subsequent identiﬁcation
of the Gimap5 gene on RNO4 were in part established
through generation of the DR.lyp congenic rat line along
with recombination events following our method of marker
assisted breeding of DP with F344 rats [2, 4, 5]. Analysis of
the lyp phenotype in the F344 DNA recombinant rats helped
us deﬁne the critical lyp interval as a region of approximately
33Kb between D4Rhw6 (76.83Mb) and IIsnp3 (77.16Mb)
containing Gimap1, Gimap5,a n dGimap3 (formerly known
asIan2,Ian5,andIan4,r esp .)[2,4].Gimap5wasidentiﬁedas
the lyp gene in the BBDP rat through a frameshift mutation
and premature truncation of the Gimap5 protein [2, 6]2 Experimental Diabetes Research
and can be rescued in a P1-derived artiﬁcial chromosome
(PAC) transgenic rat [7]. However, potential contributions
to lymphopenia and/or T1D from the other Gimap genes
are still unknown. Similarly, how the mechanisms by which
reduced Gimap5 transcript levels and the absence of the
Gimap5protein[2,7,8]contributetolymphopeniaandT1D
are still being elucidated [9–13].
The predicted structures of the Gimap proteins show
common sequences and motifs, such as GTP-binding
domains in the N-terminal half, but with diﬀering C-
terminal ends [2, 3]. Some C-terminal regions are consistent
with transmembrane domains as in the case of Gimap1 and
Gimap5, while others, as in Gimap9 and Gimap4, predict
coiled coil domains [3, 14]. Both GIMAP4 and GIMAP7
from human Jurkat cells [3] localize to the endoplasmic
reticulum and Golgi apparatus while mouse Gimap3 from
murine IL-3-dependent 32D myeloid precursor cells was
expressed at the outer mitochondrial membrane [15]. Con-
ﬂicting reports show that GIMAP5, from human primary
T cells [10] and from GIMAP5 transfected 293T cells [16],
localizes to the centrosome, Golgi apparatus, or endoplasmic
reticulum (ER), whereas Gimap5, cloned from Rat2 ﬁbrob-
lasts, localizes to a distinct subcellular fraction that is neither
mitochondrial nor ER [11]. Gimap proteins may therefore
have similar function, but diﬀerent subcellular locations.
At this time, there is a paucity of information as to the
expression of the Gimap genes in speciﬁc cell types.
The fact that the Gimap genes are located together in a
tight cluster on RNO4 (and in conserved synteny with many
other species), combined with their sequence similarities,
suggests the possibility that the proteins carry out similar
function. While there is suﬃcient evidence to support the
frameshift mutation in Gimap5 as the cause of lymphopenia,
we could not exclude that either Gimap1 or Gimap3 play
a role, as they are located within the lymphopenia critical
interval between D4Rhw6 and IIsnp3 as well as within the
PAC used in the transgenic rescue of lymphopenia [7]. In
addition, it is possible that the remaining Gimap family
membersoutsidethelymphopeniacriticalintervalplayarole
in T1D development. In order to substantiate the frameshift
mutation in Gimap5 and the subsequent protein null allele
as the cause of lymphopenia as well as explore a possible
contribution by other Gimap family members, we sequenced
DR.+/+ and DR.lyp/lyp cDNA from rat thymus. In addition, we
examined Gimap gene expression across multiple tissues and
quantiﬁed mRNA expression of all annotated and putative
Gimap genes in DR.+/+ and DR.lyp/lyp rat thymus, spleen, and
mesenteric lymph node (MLN).
2.MaterialsandMethods
2.1. DR.lyp Congenic Rats. The DR.lyp (BBDR.BBDP-
(D4Rhw17-SS99306861)( D4Rhw11-D4Rhw10)/Rhw)c o n -
genic rat line was derived from animals with two inde-
pendent recombination events developed from our pre-
viously described introgression of the lymphopenia locus
by cyclic cross-intercross breeding of BBDP with BBDR
rats [17]. The ﬁrst recombination event was ﬂanked
by simple sequence length polymorphism (SSLP) marker
D4Rhw11 (76.81Mb) and the second ﬂanked by SSLP
marker D4Rhw10 (77.81Mb) [4]. Thus, the DP DNA in
the DR.lyp rat line encompasses the lyp critical interval
from D4Rhw6 (76.83Mb) to IIsnp3 (77.16Mb) [2]. In
addition, the DR.lyp congenic rat line used in the present
study also contains BBDP DNA at D4Rat102 (66.22Mb)
and D4Rat26 (69.18 Mb). The DR.lyp congenic rat line
is kept in sister-brother breeding and produces Mendelian
proportions of the DR.lyp/lyp (25%), DR.lyp/+ (50%), and
DR.+/+ (25%) genotypes. DR.lyp/lyp are 100% lymphopenic
and 100% diabetic.
2.2. Housing. Rats were housed in a speciﬁc pathogen—
free facility at the University of Washington, Seattle,
Washington, on a 12-hour light/dark cycle with 24-hour
access to food (Harlan Teklad, Madison, Wis, USA) and
water. All protocols were approved by the institutional
animal use and care committee of the University of
Washington, Seattle, Wash, USA. The University of
Washington Rodent Health Monitoring Program was
used to track infectious agents via a quarterly sentinel
monitoring system. Excluded infectious agents are listed at
http://depts.washington.edu/compmed/rodenthealth/index.
html#excluded.
2.3. RNA Isolation. Thymus, spleen, and mesenteric lymph
nodes were homogenized from 45–78-day-old DR.lyp rats
(7 male, 8 female) immediately after dissection in RNA
lysis solution (Stratagene, La Jolla, CA or Qiagen, Valencia,
Calif, USA) either with a pestle (Kontes, Vineland, NJ, USA)
and, if viscous, passed through a 20 gauge needle or a
Kinematica Polytron PT 10/35 (Brinkmann, Westbury, NY,
USA).Bonemarrowwasobtainedbyﬂushingthefemoraand
tibia with Dulbecco’s modiﬁed medium (Life Technologies,
Grand Island, NY, USA). Nucleated cells were separated
with lympholyte-rat (1.094g/cm3, Cedarlane Lab, Ontario,
Canada) according to the manufacturer’s protocol. Total
RNAwasisolatedusingeitherRNeasy(Qiagen)orAbsolutely
RNA Miniprep Kit (Stratagene) followed by treatment with
DNase. PolyA+ RNA was isolated with Oligotex Direct
mRNA Midi/Maxi Kit, (Qiagen). Total RNA was quantitated
with RiboGreen (Stratagene).
2.4. cDNA Cloning and Sequencing. cDNA synthesis was
performed using SuperScript II Reverse Transcriptase (Invit-
rogen, Carlsbad, Calif, USA) according to the manufacturer’s
recommendations. PCR products were ampliﬁed from thy-
mus cDNA as follows: PCR products were generated by
usingeitherHerculase(Stratagene)orRocheTaqpolymerase
(Roche Diagnostics, Indianapolis, Ind, USA). Reactions with
Herculase were 25μL, consisting of 100ng cDNA, 0.5μLo f
Herculase polymerase, 2.5μL of the supplied buﬀer, 0.5μL
of a mix of 10mM each dNTP, and 2μLe a c h5μMp r i m e r .
Ampliﬁcation was carried out in a PTC-200 Peltier Thermal
Cycler (Bio-Rad, Hercules, Calif, USA) with the following
conditions: 95
◦C for 3 minutes, 35 cycles of 95
◦Cf o r3 0
seconds, 60
◦C for 30 seconds, 72
◦C for 6 minutes, andExperimental Diabetes Research 3
Table 1: Probes and primers used in qRT-PCR.
Primer name Primer sequence 5  to 3 
Gimap8-f CCAGGAGACCCAGGTGAAAG
Gimap8-r AGTTGAATGCTCATCATAGCTCCTT
Gimap8-p 6FAM-TCTGTTGACAATAGCCAATGATCTCA-BHQ1
Gimap9-f AGGAACGGCAGAGCCTACTTT
Gimap9-r CCACTAGACATTGGTTCAGCTTCTTA
Gimap9-p 6FAM-CTGACAGGATATATAAGGACA-MGBQ
Gimap4-f AACATGCCGTACAGAGCTCACA
Gimap4-r AGTGGCACCATTAGAAGGCAAA
Gimap4-p 6FAM-CCATGACACACCCACTCCAACAGGG-BHQ1
Gimap6-f TGGATGCTCTGGATGTTGCA
Gimap6-r TCCTGCTCATCCCCTTGTG
Gimap6-p 6FAM-TTGTTGAAGCCACAATGGCGTCTCTCA-BHQ1
Gimap7-f GGACTCAGTGTCAGGCTCCAA
Gimap7-r CGGGAGGACAGGCTAGCATA
Gimap7-p 6FAM-CTGGATCACACTTGGCGCTCAGCTC-BHQ1
Gimap1-f AGAGGCGGACCAGGTTCCTA
Gimap1-r CCTCCAGCCCTGCCTGTAG
Gimap1-p 6FAM-TTCTGCCATCTCCACAGCCCA-BHQ1
Gimap5-f CATGTTAGGGAAGCTCAGTC
Gimap5-r GAAGGGTTCTACTGTGTCTCA
Gimap5-p 6FAM-TTTCACTATCATTTGACTCCTGTGCA-BHQ1
Gimap3-f CCACAGGGAGTGTAGACCTTGAA
Gimap3-r CTGCTGTTTCCGAATCCAGTTT
Gimap3-p 6FAM-ATCCTCCAGCGTCCAC-MGBQ
Lr8-f GCCTCTGGTTGTGCCTTCTG
Lr8-r CCCTGTCCCATCTCATGGAT
Lr8-p 6FAM-CCCACTCCAGCCAAAATTGCCACA-BHQ1
Cyc-f CACCGTGTTCTTCGACAT
Cyc-r TTTCTGCTGTCTTTGGAACT
Cyc-p HEX-CTGCTTCGAGCTGTTTGCAGAC-BHQ1
Probes and primers were designed to bind near the 3  end of the transcripts. f is forward primer, r is reverse primer, p is probe, 6FAM is 6-carboxyﬂuorescein,
HEX is hexachloroﬂuorescein, and BHQ1 is black hole quencher 1.
aﬁ n a ls t e po f7 2
◦C for 7 minutes. Reactions with Roche
polymerase were 20μL, consisting of 100ng cDNA, 0.1μL
Roche Taq polymerase, 2.0μL of the supplied buﬀer, 0.5μL
of a mix of 10mM each dNTP, and 2μLe a c h5μMp r i m e r .
Reactions were carried out with the following conditions:
94
◦Cf o r3m i n u t e s ,3 5c y c l e so f9 4
◦C for 45 seconds, 60
◦C
for 45 seconds, 72
◦C for 2 minutes, and a ﬁnal step of
72
◦C for 7 minutes. PCR products were cloned into pCRII
withtheTOPO-TAcloningkit(Invitrogen),sequencedusing
ABI BigDye v3.1 (Applied Biosystems, Foster City, Calif,
USA), and analyzed on an ABI 3730XL sequencer (Applied
Biosystems) at the University of Washington Biochemistry
Sequencing Core in Seattle, WA. 5  and 3  RACE (5  and 3 ,
Rapid Ampliﬁcation of cDNA Ends) was carried out with a
Marathon cDNA Ampliﬁcation kit (K1802-1, Clontech, Palo
Alto, Calif, USA) using the protocol provided. Plasmids were
transformedintoXL1Blue(Stratagene)byelectroporationof
Top10 cells (Invitrogen) according to the protocol supplied
with the cells. Plasmids were puriﬁed by using GenElute
Plasmid Maxiprep Kit (Sigma, St. Louis, Mo, USA) or
Plasmid Maxi Kit (Qiagen). GenBank accession numbers of
the cloned genes and of RACE products are DQ125335–
DQ125353.
2.5. Quantitative RT-PCR. RNA was collected from whole
tissue, isolated using a Qiaqen RNeasy minikit (Valencia,
Calif, USA), and aliquoted to minimize degradation from
freezing/thawing. Quantitative real time polymerase chain
reaction (qRT-PCR) was performed on anMx4000 Multiplex
QPCR System (Stratagene) in duplex reactions with rat
cyclophilin (NM 017101) as an internal control. Samples
were run in triplicate using 100ng of total RNA or 5ng
of polyA+ RNA. Twenty-ﬁve μL reactions were run using a
Brilliant Single-Step qRT-PCR Kit (2.5μL 10x core RT-PCR
buﬀer, 5.5mM MgCl2, 300nM each primer, 200nM each
probe, 0.3mM dNTP, 75nM passive reference dye, 1.6 units
StratascriptRT,2unitsSureStartTaq DNA-polymerase).The4 Experimental Diabetes Research
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Figure 1: Expanded map of Gimap interval in human, mouse, and rat. Gimap family orthology in human, mouse, and rat is shown along
with an expanded map of the 2Mb of DP DNA in the congenic DR.lyp rat line. The 33Kb lymphopenia critical interval is indicated between
the SSLP markers D4Rhw6 and IIsnp3. Ian aliases are in parentheses underneath the corresponding Gimap name.
PCR cycling conditions were as follows: 45
◦Cf o r3 0m i n u t e s ,
95
◦C for 10 minutes, and 40 cycles of 95
◦C for 30 seconds,
60
◦C for 1 minute. Probes were positioned in the 3  regions
of the transcripts where there is more variation between the
diﬀerent Gimap genes and subjected to BLAST alignment
to ensure speciﬁcity. The primers and probes used for each
gene are listed in Table 1. Primers were obtained from
Integrated DNA Technologies (Coralville, Iowa, USA) or
Qiagen Operon (Valencia, Calif, USA). Fluorescently labeled
probes were obtained from Integrated DNA Technologies.
Representative qRT-PCR products for each gene, from each
tissue, were run on an agarose gel to check for primer
pair binding speciﬁcity. Each assay was also optimized and
validated with serial dilutions of RNA to produce a standard
curve that was then translated into a reaction eﬃciency,
or speciﬁcity, of each Gimap gene assay. Results from each
assay were validated and normalized against cyclophilin. The
standard curves, multiplexed with cyclophilin, showed the
followingreactioneﬃciencies:Gimap8:90%±2SD,Gimap7:
87% ± 4SD, Gimap4: 92% ± 2SD, Gimap6: 94% ± 3SD,
Gimap9:98%±7SD,Gimap1:100%±11SD,Gimap5:88%±
6SD,Lr8: 93% ±4SD, and cyclophilin: 90% ±6SD.
2.6. Statistical Analysis. Three DR.+/+ rats from diﬀerent
litters were used to determine the expression of Gimap
genes in mesenteric lymph node, thymus, spleen, bone
marrow, and kidney. To compare Gimap and Lr8 gene
expression across multiple tissues, data was ﬁrst normalized
to cyclophilin then scaled and expressed as a percentage of
DR.+/+ Gimap5 mesenteric lymph node (MLN), the highest
expressing gene overall. For analysis of Gimap expression
in DR.lyp/lyp,D R . lyp/+, and DR.+/+ rat thymus, spleen, and
mesenteric lymph node, 15 rats (5 rats per genotype) wereExperimental Diabetes Research 5
Table 2: Gimap family thymus cDNA sequencing in DR.
+/+ and DR.
lyp/lyp rats.
Gene
name
Location (bp) RefSeq identiﬁer mRNA
position
DR.
+/+ DR.
lyp/lyp F344 A.A Change Genbank accession #
Gimap8 76738163 NM 001033923 −96 CT 5   UTR DQ125335-36
−11 TC 5   UTR
Gimap9 76765555 NM 001008398 928 CT 3   UTR DQ125337-38
D4Rhw2 76.77
Gimap4 76777679 NM 173153 216 A G A G 72 G (Synonymous change) DQ125339-40
510 G A G T 170 T (Synonymous change)
618 G A G L 206 L (Synonymous change)
922-923 TA — —
YLN
∗
308
LELIIKAWEIASFIFNQFMRD
∗
Gimap6 76794903 NM 001011968 No SNPs DQ125342-43
Gimap7 76812445 NM 001024328 603 G A V 201 V (Synonymous change) DQ125348-49
D4Rhw6 76.82
Gimap1 76829536 NM 001034849 752 T C M 251 T DQ125350-51
Gimap5 76836521 NM 145680 252 C—
IFESKIQNQDMDKDIGNCY...
DQ125352-53 85
SSSQRSRTKTWTRTLGTAT
∗
523 C T L 175 -
IIsnp3 77.16
mRNA position is relative to the ATG start site. UTR is untranslated region.
used from 5 litters consisting of 1 rat genotype from each
litter. Mesenteric lymph node data for 1 litter was missing
leaving 12 rats from 4 litters for analysis. Comparisons
from bone marrow and kidney are not shown due to very
low expression and high error in these tissues. Pairwise
comparisons of the individual ratios were carried out using
linear mixed eﬀects models in S-PLUS (Insightful Corp.,
Seattle, Wash, USA) with a random intercept for each litter.
A conditional F-test was implemented to test the signiﬁcance
of terms in the ﬁxed eﬀects models. A two-tail test with a P-
value <.05 was judged as signiﬁcant.
2.7. Bioinformatics. Predicted protein sequences were
aligned using T-coﬀee (http://www.ch.embnet.org/software/
TCoﬀee.html). Structure and topology of proteins were
deﬁned using HMMTOP (http://www.ensim.hu./hmmtop/
index.html) or Protein Predict (http://cubic.bioc.columbia.
edu/pp/). Subcellular locations were predicted using PSORT
(http://psort.nibb.ac.jp/form2.html). The nomenclature
used in this paper follows the oﬃcial names determined
by the rat nomenclature committee (Lois J. Maltais, Mouse
Genome Database (MGD), Mouse Genome Informatics
Web Site, The Jackson Laboratory, Bar Harbor, Maine,
http://www.informatics.jax.org/) and is diﬀerent from
previous publications [2, 3, 18, 19].
3. Results
3.1. cDNA Cloning and Sequencing of Gimap8, Gimap9,
Gimap4, Gimap6, and Gimap7 in DR.+/+ and DR.lyp/lyp Rats.
Gimap8, Gimap9, Gimap4, Gimap6,a n dGimap7 (in the
orderastheyappearonthechromosome)arelocatedoutside
the lymphopenia critical interval (Figure 1). Sequence anal-
ysis of thymus cDNA encoding Gimap4 showed three single
nucleotide polymorphisms (SNPs) at positions 216, 510, and
618,relativetotheATGstartsite,andtwonucleotidesdeleted
at position 922-923 in DR.lyp/lyp rats as compared to DR.+/+
rats (Table 2). The ﬁrst three base pair substitutions resulted
in synonymous amino acid changes in the hypothetical
protein sequence, while the deletion resulted in a frameshift
mutation in the last three predicted amino acid residues and
eliminated the normal stop codon at position 311. 3  RACE
from DR.lyp/lyp thymus cDNA showed that the reading frame
continued for other 21 amino acids before generating a new
stopcodon(Table 2).Thissameframeshiftmutationwasalso
identiﬁed in F344/Rhw (nonlymphopenic) rats, which were
usedinthepositionalcloningoflymphopenia(Table 2).One
nucleotide substitution was identiﬁed in Gimap7 at position
603, relative to the ATG start site, between DR.+/+ and
DR.lyp/lyp that resulted in a synonymous amino acid change
inthehypotheticalproteinsequence(Table 2).NoSNPswere
found in the coding sequences of Gimap6, Gimap8,a n d
Gimap9.
3.2. cDNA Cloning and Sequencing of Gimap1 and Gimap3
in DR.+/+ and DR.lyp/lyp Rats. Gimap1 and Gimap3 are
located inside the lymphopenia critical interval (Figure 1).
Sequence analysis of thymic cDNA showed a single SNP
in the coding sequence of Gimap1 at nucleotide position
752, relative to the ATG start site, that produced an amino6 Experimental Diabetes Research
Gimap8A (1–250) .......... .......... .......... .......... ......... MA T S S H Q G A A AG S Q M E. H R L C E T SI G Q G E R P R A S R G Q E... .S N F K Q S Q G .
Gimap8B (251–465) .......... .......... .......... .......... .......... ... G V Q G C G T G V T Y K G D N L C G S........ K K R Q P Q I... .T G P G W D R D .
Gimap8C (466–688) .......... .......... .......... .......... .......... .......... .......... .......... .......... ......I R E K
Gimap9 .......... .......... .......... .......... .......... .......... .......... .......... .......... .... M A D Y E.
Gimap4 .......... .......... .......... .......... .......... .......... .......... M E A . Q Y S G V G SIP E N S R S S H .E L G I Q D Q G S
Gimap6 MNWLYSKTLG S IGSCCIDTL PWPFHSFFQR NLLALPGEPG NPLESSATES GKQSRSCLSA SPVME . EEGC EHSLQKNPTR QLPLDPGQEL TKDLKEKKLT
Gimap7 .......... .......... .......... .......... .......... .......... .......... .......... .......... .... M A E L D .
Gimap1 .......... .......... .......... .......... .......... ...... M G G R K M V R D .E E G A Y G S E D D S R .. .......... ......A P Q E
Gimap5 .......... .......... .......... .......... .......... .......... .......... M E G L Q K S T Y G T I V E G Q E T Y S V E....... D
Gimap8A (1–250) TSTLRLLLLG KQG
GTP GTP GTP
AGKSATG NTI LGKAVFE SRFSH. HMVT KRCQSESVSV RGKQVIV IDT PDLFS SLGC . . . PEVQQQNL RQCL . DLL . A DPYVLLLVTP
Gimap8B (251–465) TPELRVLLMG KRGVGKSAAG NS I LGKQVFK TQFSEKQRVT EAFASHSRLW NQKKFL I IDS PE I S SWKLD. . . ESDVKE . . . . . . . HTF . P GPHAFLLVTP
Gimap8C (466–688) . ELLNI I LLG RSGVGKSATG NTI LGRPAFV SQLRA.QPVT SRSQSGRRTL DW QDIVVVDT PSLNQMSGTE KNPAQLKKEI KQCLLQNCEE GMKVFVLVFQ
Gimap9 DSEMRI ILVG KTGNGKSATA NTILGKCQFD SKICA. YAVT KTCQRASRRW KGKDLVVVDT PGLFDTKES . . . LKTTCSEI SRCVLYSC. P GPHAI ILVLR
Gimap4 .P Q LRIV LL G K T G A G K SST G N SIL G R K A FL SGIC A.K SIT K V C E K G V SI W D G K EL V V V D T P GIF D T E V P. ..D A D T Q K EI T R C V A LTS.P G P H A LLL VIP
Gimap6 PKRLQLLLVG KTGSGKSATG NSILGRQVFE SKISA.RPVT M AFQKGSREL EGKELEVIDT PDILSPQ N Q. . .PEATAKKI . .CDILAS.P GPHAVLLVIQ
Gimap7 DDS LR I VLVG KTGSGKSATA NT I LGQK I FT SR I AP . HAVT QTCQKASRRW KERDLLVVDT PGL FDTKVN . . . LETTS I E I SRCVLQSC . P GPHA I I LVLQ
Gimap1 .PHLRLILVG RTGTGKSATG NSILGQKCFL SRLGA.VPVT RSCTLASRR W AGRLVEVVDT PDIFSSETPR SDPG. .CVEA ARCFVLSA.P GPHALLLVTQ
Gimap5 SGLLRILLVG KSGCGKSATG NSILRRPAFE SRLRG.QSVT RTSQAEM GT W EGRSFLVVDT PPIFESKIQ. . .NQD M DKDI GNCYLM CA.P GPHVLLLVTQ
Gimap8A (1–250) IGHSTEEDKK TI EGIQGVFG PQAYRHMIVV FTREDELGED TLQNHI ESKK . Y . LKKL I EN IGSQRCCAFN NKADKKQQEL QVSQFLDAI E FLMMESPGTY
Gimap8B (251–465) LGSSLKSGDS VFSI IKRIFG EKFIKFTI IL FTRKEDFEGQ DLDTFTKEND . .ALCNL IQI F.EGRYAVFN YRATVEEEQS QVGKLLSQIE SVVQH H NNKP
Gimap8C (466–688) LGRFTQEDEA VVEQLEASFE ENIMKYMIVL FTRKEDLGDG DLYDFTNNTK NKVLKRI FKK C. KGRVCAFN NKETGEDQET QVKALLTIAN DLKRSYD. EH
Gimap9 LDRYTEEEQK TVALIQGLFG EAALKYMI IL FTHKEDLEGQ SLDNFVDDAG . EKLNNI VSQ C.GKRYLAFN NKAAEAEQEN QVQQLIDLIE EMVARNGRAY
Gimap4 LGRYTVEEHK ATRKLLSMFE KKARRFMILL LTRKDDLEDT DIHEYLE.TA PEVLQELIYE F.RNRYCLFN NKASGAEQEE QKRQLLTLVQ SM VRENGGKY
Gimap6 VGRYTTEDQE AARCLQE I FG NGI LAYTI LV FTRKEELAEG SLEEY IKENN NKTLDALDVA C . ERRHCGFN NRAQGDEQEA XLQKLMEEIE S ILWENEGHC
Gimap7 LNRFTIEEQE TVTRIKAI FG KAVMKYLI IL FTRKDELEDQ NLNDFIEDSD . TNLKS I IKE C.DSRYLAIN NKAEGAEGEM QVQELMGFVE SLVRSNGGLY
Gimap1 LGRFTTQDSQ ALAAVKRMFG KQVMARTVVV FTRKEDLAGD SLQDYVRCTD NRALRELVAE C.GDRVCALN NRATGSESEA QVEQLLDLVA CLVREHRGTH
Gimap5 LGRYTVEDAM AVRMVKQI FG VGVMRYMIVL FTHKEDLADE SLEEFVTHTG NLDLHRLVQE C. GRRYCAFN NKASGEEQQG QLAELMALVR RLEQEHEGSF
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Gimap6 Y T M E L P N V S S K T L....... .......... .......... .......... .......... .......... .......... .......... ..........
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Figure 2: Alignment of predicted Gimap protein sequences in the DR.
+/+ rat.T - c o ﬀee predicted protein alignment from cloned cDNA is
shown. Gimap8 is divided into three separate sequences (with the amino acid numbers indicated by each sequence). Shading indicates
the GTP binding domain consensus regions (GTP) and the conserved domain (Conserved Box). The HMMTOP predicted transmembrane
domain sequences for Gimap1 and Gimap5 and the coiled coil domains for Gimap4 and Gimap9 are underlined.
acid change in DR.lyp/lyp rats as compared to the DR.+/+
(Table 2). The SNP produced a methionine (M) to threonine
(T) substitution at amino acid 251, which is located near the
C-terminus and is not in any of the predicted GTP binding
domains. Sorting intolerant from tolerant (SIFT) analysis
(http://blocks.fhcrc.org/sift/SIFT.html) predicted the T sub-
stitution to be tolerated at this position and did not predict
to aﬀect protein function.
Gimap3 is not annotated in the rat genome sequence.
Genomic sequencing of the putative ortholog of mouse
Gimap3 from base pair positions 76,846,091 to 76,852,162
onRNO4(theorthologousDNAinterval tomouse Gimap3)
in DR.+/+ and DR.lyp/lyp rats revealed repetitive single
or dinucleotide repeats throughout the region that likely
resulted in early termination of the sequencing reactions.
As such, no speciﬁc PCR products could be generated.
Attempts were also made to amplify Gimap3 from DR.+/+
and DR.lyp/lyp rat thymus cDNA; however, again, no speciﬁc
PCR products were obtained. Comparative analysis of the
Brown Norway (BN/Hsdmcwi) database sequence, available
at the University of California Santa Cruz (UCSC; Nov.
2004 assembly), with the mouse Gimap3 database sequence
(UCSC) failed to establish an open reading frame. The
multiple repetitive elements added additional diﬃculty in
locating potential exons or transcripts. No rat EST evidence
could be found in the region orthologous to mouse Gimap3
andinhuman;GIMAP3isannotatedasapseudogene. Lastly,
no evidence of a Gimap3 transcript was found in northernExperimental Diabetes Research 7
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Figure 3: Tissue speciﬁc Gimap expression. The mean ± standard
deviation is shown for DR.
+/+ (n = 3) Gimap gene expression.
To compare Gimap gene expression across multiple tissues, data
was ﬁrst normalized to cyclophilin then scaled and expressed as
ap e r c e n t a g eo fD R .
+/+ Gimap5 mesenteric lymph node (MLN),
the highest expressing gene overall. Genes appear in the order at
which they appear on rat chromosome 4. Tissues appear in the
followingorderpergene:MLN(dots),thymus(white),spleen(hash
marks), bone marrow (black), and kidney (stripes). Signiﬁcance is
represented as follows: ∗∗∗ is P<. 0001 and ∗∗ is P<. 001.
blots of DR.+/+ and DR.lyp/lyp or from qRT-PCR of DR.+/+
rat thymus or spleen (data not shown). Therefore, Gimap3 is
likely a pseudogene in rat.
3.3. Predicted Protein Alignment. Alignment of the Gimap
family predicted protein sequences in the DR.+/+ rat
(Figure 2) showed predicted GTP binding domains and
conserved box characteristics for all of the Gimap pro-
teins with the most divergent regions located near the C-
terminal ends. Gimap1 and Gimap5 are predicted to contain
transmembrane domains while Gimap4 and Gimap9 are
predicted to contain coiled coil domains. Gimap8, Gimap7,
and Gimap6 are predicted to have neither transmembrane
nor coiled coil domains. Gimap8 was larger than the other
Gimap proteins, containing 688 amino acids and three
repeated GTP binding domains (Figure 2).
3.4. Gimap Expression Pattern across Multiple Tissues. The
relative expression levels of the Gimap genes in mesenteric
lymph node, thymus, spleen, bone marrow, and kidney were
determined in the DR.+/+ rat (Figure 3). All of the Gimap
genes expressed more robustly in the mesenteric lymph
nodes, thymus, and spleen as compared to bone marrow
and kidney (P<. 0001). In the mesenteric lymph node,
Gimap4, Gimap5,a n dGimap8 were expressed signiﬁcantly
higher than Gimap9 (P<. 0001) while in kidney, Gimap4
andGimap8wereexpressedsigniﬁcantlyhigherthanGimap1
and Gimap9 (P<. 001) (Figure 3). No signiﬁcant expression
diﬀerences were detected between any of the Gimap genes
(Gimap8, 9, 4, 6, 7, 1,a n d5) in thymus, spleen, and bone
marrow. Overall, Lr8, a gene unassociated with the Gimap
family but also within the 2Mb of DP DNA in the congenic
DR.lyp/lyp rat line, expressed predominantly in the spleen, an
expression pattern unique relative to the Gimap family.
3.5. Gimap Expression in DR.lyp/lyp and DR.+/+ Thymus,
Spleen, and Mesenteric Lymph Node. In thymus, expression
of Gimap4, Gimap9, Gimap1,a n dGimap5 was signiﬁcantly
decreased in DR.lyp/lyp rats as compared to DR.+/+ (Figure 4).
In contrast, Gimap7 expression in thymus was higher in
DR.lyp/lyp as compared to DR.+/+ while Gimap8, Gimap6,a n d
Lr8showednodiﬀerentialexpression.Expressionofallofthe
Gimap genes (8, 9, 4, 6, 7, 1, and 5)w a sr e d u c e di nD R . lyp/lyp
ratspleenandmesentericlymphnodeascomparedtoDR.+/+
(Figure 4).Weobservedthesameexpressionpatternwhether
the data were normalized to cyclophilin or to total RNA
(data not shown). Data from bone marrow and kidney is not
shown due to the very low expression in these tissues. The
low expression observed in these tissues is not due to RNA
degradation, but rather to the low mRNA levels relative to
cyclophilin levels.
4. Discussion
While the frameshift mutation in Gimap5 is likely necessary
and suﬃcient for lymphopenia, the possibility remains that
additional mutation(s) in the Gimap family may contribute
to the development of lymphopenia, spontaneous T1D, or
both in the DR.lyp/lyp rat. Aside from Gimap5,o n l yGimap1
and Gimap3 could potentially play a role in the development
of lymphopenia, as they are the only remaining genes located
within the 33 Mb interval critical for lymphopenia between
D4Rhw6 and IIsnp3. The methionine to threonine base pair
substitution at amino acid position 251 in Gimap1 is not
located in any of the predicted GTP binding domains and
SIFT analysis predicted that the mutation is not likely to
alter normal Gimap1 protein function. Furthermore, the DR
amino acid at position 251 is not conserved across species;
human GIMAP1 has a valine at this same position [3].
Lastly, no Gimap3 transcript could be found and no open
readingframecouldbeidentiﬁed.Wesuspectthatthisregion
of the rat genome does not code for a protein, which is
similar to the human GIMAP3 pseudogene [3]a n du n l i k e
mouse Gimap3 [15]. Therefore, the sequence analysis of
Gimap1 and Gimap3 supports the hypothesis that Gimap5
is the cause of lymphopenia in the DR.lyp/lyp rat. In addition,
the sequence data from all of the remaining Gimap family
members suggest that these genes are not likely to play a role
in the onset of T1D diabetes. We cannot however exclude
the possibility that there are mutations outside of the coding
regions, such as in transcription factor binding sites or other
regulatory sites, that play a role in the regulation of Gimap
gene expression and/or the onset of T1D in the DR.lyp/lyp rat.
While we can exclude the involvement of the members of
the Gimap family proximal to D4Rhw6 (Gimap8, Gimap9,
Gimap4, Gimap6,a n dGimap7) in the development of
lymphopenia, we cannot exclude that they may play a role
in the development of T1D. Coding sequence analysis of
these family members revealed that only Gimap4 had genetic
diﬀerences, speciﬁcally a two-base pair deletion, that would
result in a nonsynonymous amino acid change between the
nondiabetic DR.+/+ and the diabetes susceptible DR.lyp/lyp
(Table 2). Although the eﬀect of this variation is unknown,
we did discover this same deletion in the nonlymphopenic,
diabetes resistant F344 rat. F344 DNA introgressed through
this interval on the DR.lyp/lyp background protects from8 Experimental Diabetes Research
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Figure 4: G i m a pg en ee xp r e s s i o ni nt h eD R .
+/+ and DR.
lyp/lyp rats. The mean ± standard deviation is shown for DR.
+/+ and DR.
lyp/lyp ratGimap
gene expression in thymus (n = 5), spleen (n = 5) and mesenteric lymph node (MLN) (n = 4) after normalization to cyclophilin. Black
columns represent DR.
+/+ and grey hatched columns represent DR.
lyp/lyp. Data is expressed as a percentage of DR.
+/+. Signiﬁcant diﬀerences
are follows; ∗ for P<. 05, ∗∗ for P<. 01, ∗∗∗ for P<. 001. Genes appear in the order at which they appear on rat chromosome 4. The
average Gimap expression in DR.
+/+ rat bone marrow and kidney s is shown in Figure 3.
onset of T1D [4] suggesting that the deletion mutation
in Gimap4 is not deleterious. In addition, the predicted
protein sequences of both human (AK001972) and mouse
(NP 778155.2) Gimap4 show that the 23 C-terminal amino
acids are similar to those of DR.lyp/lyp (data not shown). It
is therefore unlikely that the Gimap4 two-base pair deletion
mutation in the DR.lyp/lyp rat is functionally relevant to
development of T1D or lymphopenia, rather it is likely an
additional natural isoform [20].
All of the Gimap genes were predominantly expressed
in organs of the immune system: mesenteric lymph node,
thymus, and spleen, consistent with previous ﬁndings of a
role of the Gimap gene family in lymphocyte development
[21]. Interestingly, there was an overall reduction in expres-
sion of all seven Gimap genes in DR.lyp/lyp rat spleen and
mesentericlymphnodeandfour(Gimap4,Gimap9,Gimap1,
and Gimap5) of the seven genes in DR.lyp/lyp rat thymus. In
contrast, Lr8, a gene unrelated to the Gimap family locatedExperimental Diabetes Research 9
69 Kb downstream of Gimap5,( Figure 1)[ 22, 23] showed no
diﬀerentialexpressionbetweenDR.+/+ andDR.lyp/lyp.I tisnot
clear why Gimap5 transcript levels are reduced as the single
cytosine residue deletion results in a frameshift mutation
and a premature truncation in the protein. One hypothesis
is that during protein synthesis, the incomplete (truncated)
protein may destabilize the RNA/protein complexes and
cause mRNA degradation [24, 25]. Another hypothesis
for reduction in DR.lyp/lyp rat Gimap gene transcripts is a
diﬀerence in organ composition from those of DR.+/+ rats.
Reduced T cells numbers in DR.lyp/lyp rats could lead to
ad i ﬀerence in cellular composition and may explain the
lower observed expression of all of the Gimap genes. As the
function of Gimap proteins remains rather poorly deﬁned,
it would be a useful addendum if in vitro knockdown
experiments were designed to test the functional changes
that might derive from reduced expression of Gimap5. These
types of experiments could determine if the mutation is
signiﬁcant in functional terms or if the altered expression is
the most critical feature.
The Gimap gene family is conserved throughout evo-
lution from plants to humans [3]. Members of the Gimap
gene family are implicated in a variety of basic cellular
processes. These include protection against plant pathogens
[26] and okadaic acid and gamma radiation [16]. Gimap
family members have also been found to be important
for T cell development [27] ,Bc e l la c t i v a t i o n[ 28], B
cell malignancy [29], and apoptosis [8, 30]. In addi-
tion, Gimap5 deﬁcient mice have been shown to have
impaired maturation and survival of CD4 and CD8 positive
T cells [13].
In conclusion, positional cloning of the lymphopenia
gene in the spontaneously T1D prone BB DP rat revealed
a frameshift mutation in the GTPase Immune Associated
Protein Gimap5 [2, 6]. Our coding sequence analysis of
the remaining members of the Gimap family revealed that
Gimap4 and Gimap1 each had coding variation between
DR.+/+ and DR.lyp/lyp. However, the amino acid diﬀerences
do not appear to have functional eﬀects substantiating the
Gimap5 frameshift mutation as the cause of lymphopenia.
Quantitative real time PCR analysis showed a reduction in
expression of all seven Gimap genes in DR.lyp/lyp spleen and
mesenteric lymph nodes when compared to DR.+/+ while
only four, Gimap1, Gimap4, Gimap5, and Gimap9,w e r e
reduced in thymus. Further understanding of the nature of
the Gimap family will aid in our goal of characterizing the
pathways involved in the development of lymphopenia and
T1D.
Acknowledgments
This work was supported by the National Institutes of Health
(AI42380) and the Molecular and Genetics Core (E. A. R., B.
V., J. L. H., and M. R. P.) of the University of Washington
Diabetes and Endocrinology Research Center (DK17047),
aJ u n i o rF a c u l t yA w a r d( D .H .M ) ,a n daM e n t o rB a s e d
Postdoctoral Fellowship Award (˚ A. L.) from the American
Diabetes Association.
References
[ 1 ]H .M a r k h o l s t ,S .E a s t m a n ,D .W i l s o n ,B .E .A n d r e a s e n ,a n d
˚ A. Lernmark, “Diabetes segregates as a single locus in crosses
between inbred BB rats prone or resistant to diabetes,” The
Journal of Experimental Medicine, vol. 174, no. 1, pp. 297–300,
1991.
[ 2 ]A .J .M a c M u r r a y ,D .H .M o r a l e j o ,A .E .K w i t e k ,e ta l . ,
“Lymphopenia in the BB rat model of type 1 diabetes is due
to a mutation in a novel immune-associated nucleotide (Ian)-
related gene,” Genome Research, vol. 12, no. 7, pp. 1029–1039,
2002.
[3] J. Kr¨ ucken, R. M. U. Schroetel, I. U. M¨ uller, et al., “Compara-
tiveanalysisofthehumangimapgeneclusterencodinganovel
GTPase family,” Gene, vol. 341, no. 1-2, pp. 291–304, 2004.
[4] J. M. Fuller, A. E. Kwitek, T. J. Hawkins, et al., “Introgression
of F344 rat genomic DNA on BB rat chromosome 4 generates
diabetes-resistant lymphopenic BB rats,” Diabetes, vol. 55, no.
12, pp. 3351–3357, 2006.
[ 5 ]D .H .M o r a l e j o ,H .A .P a r k ,S .J .S p e r o s ,e ta l . ,“ G e n e t i c
dissection of lymphopenia from autoimmunity by introgres-
sion of mutated Ian5 gene onto the F344 rat,” Journal of
Autoimmunity, vol. 21, no. 4, pp. 315–324, 2003.
[6] L. Hornum, J. Rmer, and H. Markholst, “The diabetes-prone
BB rat carries a frameshift mutation in Ian4,ap o s i t i o n a l
candidate of Iddm1,” Diabetes, vol. 51, no. 6, pp. 1972–1979,
2002.
[7] M. Michalkiewicz, T. Michalkiewicz, R. A. Ettinger, et al.,
“TransgenicrescuedemonstratesinvolvementoftheIan5 gene
in T cell development in the rat,” Physiological Genomics, vol.
19, no. 2, pp. 228–232, 2004.
[8] M. Pandarpurkar, L. Wilson-Fritch, S. Corvera, et al., “Ian4
is required for mitochondrial integrity and T cell survival,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 18, pp. 10382–10387, 2003.
[9] S. Ilangumaran, M. Forand-Boulerice, S. M. Bousquet, et al.,
“LossofGIMAP5(GTPaseofimmunity-associatednucleotide
binding protein 5) impairs calcium signaling in rat T lympho-
cytes,” Molecular Immunology, vol. 46, no. 6, pp. 1256–1259,
2009.
[10] U. Dalberg, H.Markholst,and L.Hornum,“Both Gimap5 and
the diabetogenic BBDP allele of Gimap5 induce apoptosis in T
cells,” International Immunology, vol. 19, no. 4, pp. 447–453,
2007.
[11] M. Keita, C. Leblanc, D. Andrews, and S. Ramanathan,
“GIMAP5 regulates mitochondrial integrity from a dis-
tinct subcellular compartment,” Biochemical and Biophysical
Research Communications, vol. 361, no. 2, pp. 481–486, 2007.
[12] R. Kupfer, J. Lang, C. Williams-Skipp, M. Nelson, D. Bellgrau,
and R. I. Scheinman, “Loss of a gimap/ian gene leads to
activation of NF-κB through a MAPK-dependent pathway,”
Molecular Immunology, vol. 44, no. 4, pp. 479–487, 2007.
[13] R. D. Schulteis, H. Chu, X. Dai, et al., “Impaired survival of
peripheral T cells, disrupted NK/NKT cell development, and
liver failure in mice lacking Gimap5,” Blood, vol. 112, no. 13,
pp. 4905–4914, 2008.
[14] O. Stamm, J. Kr¨ ucken, H.-P. Schmitt-Wrede, W. P. M. Benten,
and F. Wunderlich, “Human ortholog to mouse gene imap38
encoding an ER-localizable G-protein belongs to a gene family
clustered on chromosome 7q32-36,” Gene, vol. 282, no. 1-2,
pp. 159–167, 2002.
[15] L. Dah´ eron, T. Zenz, L. D. Siracusa, C. Brenner, and B.
Calabretta, “Molecular cloning of Ian4: a BCR/ABL-induced
gene that encodes an outer membrane mitochondrial protein10 Experimental Diabetes Research
with GTP-binding activity,” Nucleic Acids Research, vol. 29, no.
6, pp. 1308–1316, 2001.
[16] T. Sandal, L. Aumo, L. Hedin, B. T. Gjertsen, and S. O.
Døskeland, “Irod/Ian5: an inhibitor of γ-radiation- and
okadaic acid-induced apoptosis,” Molecular Biology of the Cell,
vol. 14, no. 8, pp. 3292–3304, 2003.
[ 1 7 ]S .B i e g ,G .K o i k e ,J .J i a n g ,e ta l . ,“ G e n e t i ci s o l a t i o no fiddm 1
on chromosome 4 in the biobreeding (BB) rat,” Mammalian
Genome, vol. 9, no. 4, pp. 324–326, 1998.
[18] J. Kr¨ ucken, M. Epe, W. P. M. Benten, N. Falkenroth, and
F. Wunderlich, “Malaria-suppressible expression of the anti-
a p o p t o t i ct r i p l eG T P a s em G I M A P 8 , ”Journal of Cellular
Biochemistry, vol. 96, no. 2, pp. 339–348, 2005.
[19] T. Nitta, M. Nasreen, T. Seike, et al., “IAN family critically
regulates survival and development of T lymphocytes,” PLoS
Biology, vol. 4, no. 4, article e103, pp. 1–13, 2006.
[20] C. Carter, C. Dion, S. Schnell, et al., “A natural hypomorphic
variant of the apoptosis regulator Gimap4/IAN1,” The Journal
of Immunology, vol. 179, no. 3, pp. 1784–1795, 2007.
[21] J.-J. Fil´ en, S. FiL´ en, R. Moulder, et al., “Quantitative pro-
teomics reveals GIMAP family proteins 1 and 4 to be diﬀer-
entially regulated during human T helper cell diﬀerentiation,”
Molecular & Cellular Proteomics, vol. 8, no. 1, pp. 32–44, 2009.
[22] J. Lurton, T. M. Rose, G. Raghu, and A. S. Narayanan,
“Isolation of a gene product expressed by a subpopulation
of human lung ﬁbroblasts by diﬀerential display,” American
Journal of Respiratory Cell and Molecular Biology, vol. 20, no.
2, pp. 327–331, 1999.
[23] H. Nakajima, M. Takenaka, J.-Y. Kaimori, et al., “Gene
expression proﬁle of renal proximal tubules regulated by
proteinuria,” Kidney International, vol. 61, no. 5, pp. 1577–
1587, 2002.
[24] P. A. Frischmeyer and H. C. Dietz, “Nonsense-mediated
mRNA decay in health and disease,” Human Molecular
Genetics, vol. 8, no. 10, pp. 1893–1900, 1999.
[25] J. T. Mendell, N. A. Shariﬁ, J. L. Meyers, F. Martinez-
Murillo, and H. C. Dietz, “Nonsense surveillance regulates
expression of diverse classes of mammalian transcripts and
mutes genomic noise,” Nature Genetics, vol. 36, no. 10, pp.
1073–1078, 2004.
[26] T.L.ReuberandF.M.Ausubel,“Isolationofarabidopsisgenes
thatdiﬀerentiatebetweenresistanceresponsesmediatedbythe
RPS2 and RPM1 disease resistance genes,” The Plant Cell, vol.
8, no. 2, pp. 241–249, 1996.
[27] G. M. C. Poirier, G. Anderson, A. Huvar, et al., “Immune-
associated nucleotide-1 (IAN-1) is a thymic selection marker
and deﬁnes a novel gene family conserved in plants,” The
Journal of Immunology, vol. 163, no. 9, pp. 4960–4969, 1999.
[ 2 8 ]M .C a m b o t ,S .A r e s t a ,B .K a h n - P e r l ` es, J. de Gunzburg, and
P.-H. Rom ´ eo, “Human immune associated nucleotide 1: a
member of a new guanosine triphosphatase family expressed
in resting T and B cells,” Blood, vol. 99, no. 9, pp. 3293–3301,
2002.
[29] T. Zenz, A. Roessner, A. Thomas, et al., “hlan5: the human
ortholog to the rat lan4/lddm1/lyp is a new member of the Ian
family that is overexpressed in B-cell lymphoid malignancies,”
Genes & Immunity, vol. 5, no. 2, pp. 109–116, 2004.
[30] J. A. Lang, D. Kominski, D. Bellgrau, and R. I. Scheinman,
“Partial activation precedes apoptotic death in T cells harbor-
ing an IAN gene mutation,” European Journal of Immunology,
vol. 34, no. 9, pp. 2396–2406, 2004.